BRPI0821114A2 - Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer - Google Patents

Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer

Info

Publication number
BRPI0821114A2
BRPI0821114A2 BRPI0821114-0A BRPI0821114A BRPI0821114A2 BR PI0821114 A2 BRPI0821114 A2 BR PI0821114A2 BR PI0821114 A BRPI0821114 A BR PI0821114A BR PI0821114 A2 BRPI0821114 A2 BR PI0821114A2
Authority
BR
Brazil
Prior art keywords
compound
cancer
treat
affected mammal
mammal
Prior art date
Application number
BRPI0821114-0A
Other languages
English (en)
Inventor
Alberto Rodrígues Vicente
María Garranzo García-Ibarrola
Carmen Murcia Pérez
Francisco Sánchez Sancho
María Del Carmen Cuevas Marchante
Cristina Mateo Urbano
Isabel Digón Juárez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BRPI0821114A2 publication Critical patent/BRPI0821114A2/pt
Publication of BRPI0821114B1 publication Critical patent/BRPI0821114B1/pt
Publication of BRPI0821114B8 publication Critical patent/BRPI0821114B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0821114A 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto BRPI0821114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
EP07123882.8 2007-12-20
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (3)

Publication Number Publication Date
BRPI0821114A2 true BRPI0821114A2 (pt) 2015-06-16
BRPI0821114B1 BRPI0821114B1 (pt) 2021-09-08
BRPI0821114B8 BRPI0821114B8 (pt) 2021-11-09

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0821116A BRPI0821116B8 (pt) 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0821114A BRPI0821114B8 (pt) 2007-12-20 2008-12-19 Composto antitumoral, composição farmacêutica, uso de um composto antitumoral, uso de uma composição farmacêutica, e processo para a preparação do referido composto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0821116A BRPI0821116B8 (pt) 2007-12-20 2008-12-19 composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo

Country Status (27)

Country Link
US (4) US8710264B2 (pt)
EP (3) EP2231590B9 (pt)
JP (3) JP5727228B2 (pt)
KR (3) KR101579553B1 (pt)
CN (4) CN102190643B (pt)
AT (1) ATE549313T1 (pt)
AU (2) AU2008341671B2 (pt)
BR (2) BRPI0821116B8 (pt)
CA (2) CA2715203C (pt)
CY (1) CY1117245T1 (pt)
DK (2) DK2231633T3 (pt)
ES (3) ES2442140T3 (pt)
HK (3) HK1147990A1 (pt)
HR (2) HRP20120464T1 (pt)
IL (3) IL206397A (pt)
MX (2) MX2010006795A (pt)
MY (3) MY164533A (pt)
NZ (3) NZ597526A (pt)
PL (2) PL2231590T3 (pt)
PT (2) PT2231590E (pt)
RS (2) RS52343B (pt)
RU (3) RU2489429C2 (pt)
SG (2) SG170778A1 (pt)
SI (2) SI2231590T1 (pt)
UA (3) UA119963C2 (pt)
WO (2) WO2009080769A1 (pt)
ZA (3) ZA201004018B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597526A (en) 2007-12-20 2012-06-29 Pharma Mar Sa Antitumoral compounds
JP6180115B2 (ja) 2012-01-05 2017-08-16 花王株式会社 刺激感緩和剤
BR112015026261A8 (pt) 2013-04-16 2017-12-26 Actelion Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
WO1992012140A1 (en) * 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質S−59917a及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
CA2401104A1 (en) * 2000-04-04 2001-10-11 Novartis Ag Method for treating cells resistant to antineoplastic agents
NZ567758A (en) * 2002-03-04 2009-07-31 Merck Hdac Res Llc Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA)
MXPA06000975A (es) * 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
BRPI0722429A2 (pt) * 2006-06-16 2013-11-26 Pharma Mar Sa Processo para a preparação de um composto de di-hidropiran-2-ona, processo para a preparação de compostos intermediários, e compostos de fragmentos
NZ597526A (en) 2007-12-20 2012-06-29 Pharma Mar Sa Antitumoral compounds

Also Published As

Publication number Publication date
CN101903367A (zh) 2010-12-01
ZA201106371B (en) 2013-05-29
RU2528393C1 (ru) 2014-09-20
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
RU2528393C9 (ru) 2015-01-10
ES2578606T3 (es) 2016-07-28
US9187445B2 (en) 2015-11-17
SG170779A1 (en) 2011-05-30
BRPI0821116B1 (pt) 2020-02-18
UA104281C2 (ru) 2014-01-27
PL2231633T3 (pl) 2014-03-31
RS52343B (en) 2012-12-31
BRPI0821114B1 (pt) 2021-09-08
US20150344454A1 (en) 2015-12-03
IL206396A0 (en) 2010-12-30
CN101903337B (zh) 2013-12-18
CA2710087A1 (en) 2009-07-02
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
EP2231633A1 (en) 2010-09-29
MY155342A (en) 2015-10-15
CN101903367B (zh) 2015-08-05
IL206396A (en) 2014-05-28
BRPI0821114B8 (pt) 2021-11-09
JP2011506578A (ja) 2011-03-03
WO2009080761A1 (en) 2009-07-02
MX2010006795A (es) 2010-10-26
US20120041063A2 (en) 2012-02-16
HK1147990A1 (en) 2011-08-26
ES2442140T3 (es) 2014-02-25
IL206397A0 (en) 2010-12-30
JP2011506575A (ja) 2011-03-03
CN102190643B (zh) 2015-02-25
CN101903337A (zh) 2010-12-01
BRPI0821116A2 (pt) 2015-08-11
KR101639772B1 (ko) 2016-07-15
SI2231590T1 (sl) 2012-10-30
EP2231590A1 (en) 2010-09-29
EP2597091B1 (en) 2016-04-20
DK2231633T3 (da) 2014-01-20
HRP20140015T1 (hr) 2014-02-14
RU2013112003A (ru) 2014-08-20
MY148651A (en) 2013-05-15
IL229594A (en) 2016-02-29
EP2231590B9 (en) 2012-08-15
EP2231590B1 (en) 2012-03-14
EP2231633B1 (en) 2013-10-30
IL229594A0 (en) 2014-01-30
CA2715203A1 (en) 2009-07-02
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
KR20150076265A (ko) 2015-07-06
CN102190643A (zh) 2011-09-21
AU2008341670B2 (en) 2012-04-19
AU2008341671B2 (en) 2012-07-26
JP5860088B2 (ja) 2016-02-16
US9827257B2 (en) 2017-11-28
US8710264B2 (en) 2014-04-29
NZ586013A (en) 2012-02-24
HRP20120464T1 (hr) 2012-07-31
JP2014133752A (ja) 2014-07-24
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
PL2231590T3 (pl) 2012-09-28
KR101541436B1 (ko) 2015-08-03
JP5727228B2 (ja) 2015-06-03
RU2493147C2 (ru) 2013-09-20
DK2231590T3 (da) 2012-07-09
AU2008341670A1 (en) 2009-07-02
US9750759B2 (en) 2017-09-05
SG170778A1 (en) 2011-05-30
MY164533A (en) 2017-12-29
CA2715203C (en) 2015-09-08
ZA201004018B (en) 2011-12-28
CA2710087C (en) 2015-06-02
ZA201004017B (en) 2011-12-28
PT2231590E (pt) 2012-06-25
EP2597091A1 (en) 2013-05-29
AU2008341671A1 (en) 2009-07-02
US20150342972A1 (en) 2015-12-03
RS53140B (en) 2014-06-30
UA106967C2 (uk) 2014-11-10
CN102174058A (zh) 2011-09-07
HK1147998A1 (en) 2011-08-26
UA119963C2 (uk) 2019-09-10
CY1117245T1 (el) 2017-04-05
BRPI0821116B8 (pt) 2021-05-25
ATE549313T1 (de) 2012-03-15
RU2010130180A (ru) 2012-01-27
ES2384420T3 (es) 2012-07-04
SI2231633T1 (sl) 2014-02-28
HK1180678A1 (zh) 2013-10-25
RU2010130253A (ru) 2012-01-27
JP5529038B2 (ja) 2014-06-25
US20110034549A1 (en) 2011-02-10
KR20100125226A (ko) 2010-11-30
MX2010006796A (es) 2010-10-26
IL206397A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CO6270257A2 (es) Derivados de piridazinona
EP1961418A4 (en) USE OF ISOTHIOCYANATE-BASED COMPOUNDS IN THE TREATMENT OF PROSTATIC DISEASES AND SKIN CANCER
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
WO2006125815A3 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
MX2010012593A (es) Metodos para el tratamiento de lesion asociada con exposicion a especie alcalina.
WO2010149688A3 (en) Antitumoral compounds
BRPI0516423A (pt) benzimidazóis substituìdos para o tratamento da histomìase
ATE547414T1 (de) 4-oxadiazolylpiperidinverbindungen und deren verwendung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2644, QUANTO AO NOME DE INVENTOR